110 related articles for article (PubMed ID: 10594470)
41. Relationship between acceleration of gastric emptying and oesophageal acid exposure in patients with endoscopy-negative gastro-oesophageal reflux disease.
Carmagnola S; Fraquelli M; Cantù P; Conte D; Penagini R
Scand J Gastroenterol; 2006 Jul; 41(7):767-72. PubMed ID: 16785188
[TBL] [Abstract][Full Text] [Related]
42. Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.
Csajka C; Marzolini C; Fattinger K; Décosterd LA; Telenti A; Biollaz J; Buclin T
Antimicrob Agents Chemother; 2004 Sep; 48(9):3226-32. PubMed ID: 15328077
[TBL] [Abstract][Full Text] [Related]
43. Population pharmacokinetics of rectal theophylline in neonates.
Karlsson MO; Thomson AH; McGovern EM; Chow P; Evans TJ; Kelman AW
Ther Drug Monit; 1991 May; 13(3):195-200. PubMed ID: 1926271
[TBL] [Abstract][Full Text] [Related]
44. Cisapride: influence on oesophageal and gastric emptying and gastro-oesophageal reflux in patients with reflux oesophagitis.
Collins BJ; Spence RA; Ferguson R; Laird J; Love AH
Hepatogastroenterology; 1987 Jun; 34(3):113-6. PubMed ID: 3301606
[TBL] [Abstract][Full Text] [Related]
45. [Population pharmacokinetics of lamotrigine in Chinese children with epilepsy].
Zhang S; Wang L; Lu W
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Apr; 10(2):105-9. PubMed ID: 18433522
[TBL] [Abstract][Full Text] [Related]
46. Cochrane's epitaph for cisapride in childhood gastro-oesophageal reflux.
Bourke B; Drumm B
Arch Dis Child; 2002 Feb; 86(2):71-2. PubMed ID: 11827895
[No Abstract] [Full Text] [Related]
47. Effects of ranitidine and cisapride on acid reflux and oesophageal motility in patients with reflux oesophagitis: a 24 hour ambulatory combined pH and manometry study.
Inauen W; Emde C; Weber B; Armstrong D; Bettschen HU; Huber T; Scheurer U; Blum AL; Halter F; Merki HS
Gut; 1993 Aug; 34(8):1025-31. PubMed ID: 8174947
[TBL] [Abstract][Full Text] [Related]
48. Ropivacaine in neonates and infants: a population pharmacokinetic evaluation following single caudal block.
Rapp HJ; Molnár V; Austin S; Krohn S; Gädeke V; Motsch J; Boos K; Williams DG; Gustafsson U; Huledal G; Larsson LE
Paediatr Anaesth; 2004 Sep; 14(9):724-32. PubMed ID: 15330953
[TBL] [Abstract][Full Text] [Related]
49. Population pharmacokinetics of mavacoxib in osteoarthritic dogs.
Cox SR; Liao S; Payne-Johnson M; Zielinski RJ; Stegemann MR
J Vet Pharmacol Ther; 2011 Feb; 34(1):1-11. PubMed ID: 21219337
[TBL] [Abstract][Full Text] [Related]
50. Population pharmacokinetics of epinastine, a histamine H1 receptor antagonist, in adults and children.
Sarashina A; Tatami S; Yamamura N; Tsuda Y; Igarashi T
Br J Clin Pharmacol; 2005 Jan; 59(1):43-53. PubMed ID: 15606439
[TBL] [Abstract][Full Text] [Related]
51. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.
de Maat MM; Huitema AD; Mulder JW; Meenhorst PL; van Gorp EC; Beijnen JH
Br J Clin Pharmacol; 2002 Oct; 54(4):378-85. PubMed ID: 12392585
[TBL] [Abstract][Full Text] [Related]
52. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes.
Hesselink DA; van Gelder T; van Schaik RH; Balk AH; van der Heiden IP; van Dam T; van der Werf M; Weimar W; Mathot RA
Clin Pharmacol Ther; 2004 Dec; 76(6):545-56. PubMed ID: 15592326
[TBL] [Abstract][Full Text] [Related]
53. Population pharmacokinetics of oral busulfan in children.
Schiltmeyer B; Klingebiel T; Schwab M; Mürdter TE; Ritter CA; Jenke A; Ehninger G; Gruhn B; Würthwein G; Boos J; Hempel G
Cancer Chemother Pharmacol; 2003 Sep; 52(3):209-16. PubMed ID: 12811512
[TBL] [Abstract][Full Text] [Related]
54. Gaviscon and Carobel compared with cisapride in gastro-oesophageal reflux.
Greally P; Hampton FJ; MacFadyen UM; Simpson H
Arch Dis Child; 1992 May; 67(5):618-21. PubMed ID: 1599300
[TBL] [Abstract][Full Text] [Related]
55. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease.
Rosario M; Dirks NL; Gastonguay MR; Fasanmade AA; Wyant T; Parikh A; Sandborn WJ; Feagan BG; Reinisch W; Fox I
Aliment Pharmacol Ther; 2015 Jul; 42(2):188-202. PubMed ID: 25996351
[TBL] [Abstract][Full Text] [Related]
56. Bioavailability of three oral dosage forms of cisapride, a gastrointestinal stimulant agent.
Barone JA; Huang YC; Bierman RH; Colaizzi JL; Long JF; Kerr DA; Van Peer A; Woestenborghs R; Heykants J
Clin Pharm; 1987 Aug; 6(8):640-5. PubMed ID: 3691010
[TBL] [Abstract][Full Text] [Related]
57. Population pharmacokinetics of higher-dose mizoribine in healthy male volunteers.
Honda M; Itoh H; Suzuki T; Hashimoto Y
Biol Pharm Bull; 2006 Dec; 29(12):2460-4. PubMed ID: 17142982
[TBL] [Abstract][Full Text] [Related]
58. Influence of coadministration of fluoxetine on cisapride pharmacokinetics and QTc intervals in healthy volunteers.
Zhao Q; Wojcik MA; Parier JL; Pesco-Koplowitz L
Pharmacotherapy; 2001 Feb; 21(2):149-57. PubMed ID: 11213850
[TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetics of metoclopramide in neonates.
Kearns GL; van den Anker JN; Reed MD; Blumer JL
J Clin Pharmacol; 1998 Feb; 38(2):122-8. PubMed ID: 9549642
[TBL] [Abstract][Full Text] [Related]
60. Population pharmacokinetics of primaquine and the effect of hepatic and renal dysfunction: An exploratory approach.
Sridharan K; Sannala CKR; Mallayasamy S; Chaturvedula A; Kadam P; Hase N; Shukla A; Gogtay N; Thatte U
Indian J Pharmacol; 2019; 51(1):17-24. PubMed ID: 31031463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
